Skip to content
CompletedNot applicableResults posted

Treatment of Suicidal Ideation With Intravenous Ketamine Infusion

NCT01887990 · University of Alabama at Birmingham

Closed to entry
Status
Not accepting participants
Not applicable
Phase
18
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

This study is dedicated to achieving better treatments for suicidal thoughts. Specifically, the investigators are studying the effect of a medication called ketamine to quickly treat suicidal thoughts and depression.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Suicidality

    Measured over 2 hours

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

19 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Age : 19-64 2. Significant suicidality score on the Columbia Suicide Severity Rating Scale (C-SSRS) 3. Willing and able to provide informed consent. 4. Individuals with current substance abuse are allowed Exclusion Criteria: 1. Pregnant or lactating; women of reproductive potential must have a negative urine pregnancy test (urine dipstick method) 2. Post-Partum state : defined as being within 2 months of delivery or miscarriage 3. Homicide risk as determined by clinical interview 4. Treatment with any medication known to specifically target the glutamate-NMDA receptor system (ie lamotrigine, acamprosate, memantine, riluzole or lithium) 5. Any known hypersensitivity or serious adverse effect associated with ketamine treatment. 6. Any clinically significant medical condition or therapy that would preclude treatment with ketamine, to include recent myocardial infarction or unstable angina 7. Medically unstable, including acute withdrawal from alcohol or benzodiazepines requiring the use of benzodiazepine treatment. 8. Any of the following DSM-IV diagnoses or categories: * Any current psychosis or history of a non-mood psychotic disorder (e.g., schizophrenia) * Currently in a manic or mixed episode * Current use (defined by urine dipstick test) or abuse of hallucinogenic drugs (except marijuana) such as phencyclidine * Any dissociative disorder * Any pervasive developmental disorder (e.g., autism) * A cognitive disorder (e.g., Alzheimer's Disease) * Cluster A personality disorder (e.g., schizoid or schizotypal); note that cluster B and C personality disorders may be included * Any eating disorder

Where

1 study site

FacilityCityRegionCountry
University of Alabama BirminghamBirminghamAlabamaUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT01887990 on ClinicalTrials.gov →

Last updated in the registry 2017-05-15. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits